SG/CALL/ABBVIE/160/0.1/20.09.24 Stock

Warrant

DE000SQ8Z498

Delayed Deutsche Boerse AG 09:27:30 2024-07-03 EDT
0.92 EUR -8.91% Intraday chart for SG/CALL/ABBVIE/160/0.1/20.09.24
Current month-21.71%
1 month+46.38%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-07-03 0.92 -8.91%
24-07-02 1.01 -19.84%
24-07-01 1.26 -2.33%
24-06-28 1.29 +6.61%
24-06-27 1.21 -15.38%

Delayed Quote Deutsche Boerse AG

Last update July 03, 2024 at 09:27 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ABBVIE INC.
IssuerLogo Issuer Société Générale Société Générale
WKN SQ8Z49
ISINDE000SQ8Z498
Date issued 2023-02-13
Strike 160 $
Maturity 2024-09-20 (79 Days)
Parity 10 : 1
Emission price 1.44
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 2.53
Lowest since issue 0.36
Delta0.65x
Omega 10.32
Premium2.74x
Gearing15.78x
Moneyness 1.037
Difference Strike -5.85 $
Difference Strike %-3.66%
Spread 0.11
Spread %10.68%
Intrinsic value 0.5948

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
-
More about the company

Ratings for AbbVie Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: AbbVie Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
166 USD
Average target price
183.2 USD
Spread / Average Target
+10.41%
Consensus